A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 20, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 20-F for FY2025, filed Apr 30, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the PRE SEC filings page.
Prenetics Global Limited (PRE) reported $92.4M in revenue for fiscal year 2025, up 201.7% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (20-F and 6-K reports).
Prenetics has reached rapid revenue scale and higher gross margins, but operations still consume cash and remain far from breakeven.
The key earnings-quality gap is that FY2025’s operating cash flow was-$21.8M and free cash flow was-$22.0M , even though capital expenditures were only$208K , or0.2% of revenue. Cash consumption therefore came chiefly from the operating model itself, not from heavy reinvestment in equipment.
Revenue expanded
The cost structure is changing: research and development fell
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed: here 4 of 6, with the others left out rather than counted as zero. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Prenetics Global Limited's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Not available for Prenetics Global Limited, so it is left out of the overall score, which averages the 4 of 6 dimensions that can be computed.
Dilution ranks emerging companies on the yearly rate at which their shares outstanding grew across the last three fiscal years (the last two where the earliest reports none), a slower rise ranking higher because each round of funding spreads the same business across more owners. Prenetics Global Limited scores 44/100 on it among other emerging companies.
Prenetics Global Limited spent $5.1M on research and development in fiscal year 2025, which was 3.7% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Prenetics Global Limited scores 22/100 among other emerging companies.
Revenue Progress ranks emerging companies on the yearly rate at which their revenue compounded across the last three fiscal years (the last two where the earliest reports none), counted in the currency each company reports in. Prenetics Global Limited scores 87/100 on it among other emerging companies.
Burn Trend ranks emerging companies on how far their operating cash flow moved between the newest fiscal year and the one two years earlier, measured against the cash the earlier year used, and a move toward generating cash ranks higher. Prenetics Global Limited scores 29/100 on it among other emerging companies.
Not available for Prenetics Global Limited, so it is left out of the overall score, which averages the 4 of 6 dimensions that can be computed.
Prenetics Global Limited passes 5 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.
Prenetics Global Limited reported a net loss of $37.7M while operations used $21.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Prenetics Global Limited reported an operating loss of $44.5M against $258K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Prenetics Global Limited generated $92.4M in revenue in fiscal year 2025. This represents an increase of 201.7% from the prior year.
Prenetics Global Limited reported a net loss of $37.7M in fiscal year 2025. The change from the prior year is not meaningful, because that figure was zero or negative.
Prenetics Global Limited earned -$2.68 per diluted share (EPS) in fiscal year 2025. The change from the prior year is not meaningful, because that figure was zero or negative.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Prenetics Global Limited recorded an outflow of $22.0M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. The change from the prior year is not meaningful, because that figure was zero or negative.
Prenetics Global Limited held $32.1M in cash as of fiscal year 2025; no long-term debt figure is on record for that period.
Not reported for fiscal year 2025.
Margins & Returns
Prenetics Global Limited's gross margin was 52.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 2.5 percentage points from the prior year.
Prenetics Global Limited's operating margin was -48.1% in fiscal year 2025, reflecting core business profitability. No change is given against fiscal year 2024: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Prenetics Global Limited's net profit margin was -40.8% in fiscal year 2025, showing the share of revenue converted to profit. No change is given against fiscal year 2024: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Prenetics Global Limited's ROE was -24.1% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 3.1 percentage points from the prior year.
Capital Allocation
Prenetics Global Limited invested $5.1M in research and development in fiscal year 2025. This represents a decrease of 53.0% from the prior year.
Prenetics Global Limited invested $208K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 79.3% from the prior year.
Not reported for fiscal year 2025.
PRE Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F |
|---|---|---|---|---|---|---|
| Revenue | $92.4M+201.7% | $30.6M+40.8% | $21.7M+65.2% | $13.2M+5.0% | $12.5M-80.8% | $65.2M |
| Cost of Revenue | $43.6M+186.4% | $15.2M+17.9% | $12.9M+35.3% | $9.5M+6.9% | $8.9M-77.0% | $38.8M |
| Gross Profit | $48.8M+216.8% | $15.4M+74.4% | $8.8M+144.1% | $3.6M+0.4% | $3.6M-86.3% | $26.3M |
| R&D Expenses | $5.1M-53.0% | $10.9M-6.3% | $11.7M+94.7% | $6.0M-6.3% | $6.4M+129.7% | $2.8M |
| Operating Income | -$44.5Mn/m | -$48.1Mn/m | -$51.9Mn/m | -$66.0Mn/m | -$56.7Mn/m | -$995K |
| Interest Expense | $258K+27.1% | $203K-16.1% | $242K-94.2% | $4.2M-19.9% | $5.2M+8693.5% | $60K |
| Income Tax | $34Kn/m | -$7.9Mn/m | -$269Kn/m | -$245K-109.5% | $2.6Mn/m | -$1.9M |
| Net Income | -$37.7Mn/m | -$46.3Mn/m | -$62.7Mn/m | -$190.5Mn/m | -$174.0Mn/m | -$1.9M |
| EPS (Basic) | -$2.68n/m | -$3.71n/m | -$5.58 | -$37.57 | -$178.81n/m | -$2.25 |
| EPS (Diluted) | -$2.68n/m | -$3.71n/m | -$5.58 | -$37.57 | -$178.81n/m | -$2.25 |
| Diluted Shares (Avg) | 14M+12.5% | 12M+11.1% | 11M | 5M | N/A | N/A |
Not reported in any period shown, so not listed: SG&A Expenses, EBITDA.
PRE Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F |
|---|---|---|---|---|---|---|
| Total Assets | $206.1M-3.5% | $213.6M-16.0% | $254.2M-18.6% | $312.1M+110.2% | $148.5M | N/A |
| Current Assets | $85.2M-1.1% | $86.1M-8.0% | $93.7M-61.3% | $241.8M+126.2% | $106.9M | N/A |
| Cash & Equivalents | $32.1M-38.5% | $52.3M+14.3% | $45.7M-68.8% | $146.7M+315.6% | $35.3M+143.5% | $14.5M |
| Inventory | $7.0M+7.1% | $6.6M+110.0% | $3.1M-31.0% | $4.5M-33.6% | $6.8M | N/A |
| Accounts Receivable | $14.8M-11.5% | $16.8M-5.0% | $17.7M-66.8% | $53.2M-3.1% | $54.9M | N/A |
| Goodwill | $1.4M-96.3% | $37.4M+28.1% | $29.2M-13.7% | $33.8M+749.7% | $4.0M-0.4% | $4.0M |
| Total Liabilities | $49.7M+17.7% | $42.2M-4.1% | $44.0M-35.9% | $68.7M-87.5% | $549.4M | N/A |
| Current Liabilities | $28.7M-21.4% | $36.6M-7.4% | $39.5M-31.0% | $57.2M-2.6% | $58.7M | N/A |
| Non-Current Liabilities | $21.0M+269.7% | $5.7M+25.4% | $4.5M-60.5% | $11.5M-97.7% | $490.7M | N/A |
| Total Equity | $156.5M-8.2% | $170.4M-17.4% | $206.4M-13.0% | $237.1Mn/m | -$400.8M-1392.6% | $31.0M |
Not reported in any period shown, so not listed: Short-Term Investments, Long-Term Investments, Long-Term Debt, Retained Earnings.
PRE Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -$21.8Mn/m | -$28.9Mn/m | -$13.8M-194.8% | $14.5M+8.2% | $13.4Mn/m | -$2.9M |
| Capital Expenditures | $208K-79.3% | $1.0M+191.6% | $345K-93.0% | $4.9M-42.1% | $8.5M+198.5% | $2.9M |
| Free Cash Flow | -$22.0Mn/m | -$29.9Mn/m | -$14.1M-247.5% | $9.6M+96.5% | $4.9Mn/m | -$5.7M |
| Investing Cash Flow | -$35.7M-192.6% | $38.5Mn/m | -$83.0Mn/m | -$46.1Mn/m | -$22.0Mn/m | -$6.0M |
| Financing Cash Flow | $37.5Mn/m | -$3.3Mn/m | -$4.7M-103.3% | $143.3M+388.9% | $29.3M+147.5% | $11.8M |
Not reported in any period shown, so not listed: Depreciation & Amortization, Stock-Based Compensation, Dividends Paid, Share Buybacks.
PRE Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F |
|---|---|---|---|---|---|---|
| Gross Margin | 52.8%+2.5pp | 50.3%+9.7pp | 40.6%+13.1pp | 27.5%-1.3pp | 28.7%-11.7pp | 40.4% |
| Operating Margin | -48.1% | -157.2% | -238.7% | -501.5% | -452.1% | -1.5% |
| Net Margin | -40.8% | -151.2% | -288.5% | -1446.8% | -1388.4% | -3.0% |
| Return on Equity | -24.1%+3.1pp | -27.2%+3.2pp | -30.4%+49.9pp | -80.3% | N/A | -6.3% |
| Return on Assets | -18.3%+3.4pp | -21.7%+3.0pp | -24.7%+36.3pp | -61.0%+56.1pp | -117.2% | N/A |
| Current Ratio | 2.97+0.6x | 2.360.0x | 2.37-1.9x | 4.23+2.4x | 1.82 | N/A |
| Liabilities-to-Equity | 0.32+0.1x | 0.250.0x | 0.21-0.1x | 0.29 | N/A | N/A |
| Asset Turnover | 0.45+0.3x | 0.14+0.1x | 0.090.0x | 0.040.0x | 0.08 | N/A |
| FCF Margin | -23.8%+73.7pp | -97.6%-32.7pp | -64.9%-137.6pp | 72.7%+33.8pp | 38.9%+47.7pp | -8.8% |
Not reported in any period shown, so not listed: Debt-to-Equity.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Prenetics Global Limited PRE | FY2025 | $92.4M | -$37.7M | -40.8% | $171.7M | 46/100 |
| Lifeway Foods Inc LWAY | FY2025 | $212.5M | $13.9M | 6.5% | $289.6M | 63/100 |
| Mama's Creations, Inc. MAMA | FY2026 | $171.7M | $5.3M | 3.1% | $522.4M | 68/100 |
| John B. Sanfilippo & SON JBSS | FY2026 | $1.2B | $61.9M | 5.3% | $714.1M | 62/100 |
| Westrock Coffee Company WEST | FY2025 | $1.2B | -$90.4M | -7.6% | $722.5M | 25/100 |
| Enhanced Group Inc. ENHA | FY2025 | N/A | -$26.7M | N/A | $240.6M | — |
Where Prenetics Global Limited Ranks
Frequently Asked Questions
Prenetics Global Limited (PRE) reported $92.4M in total revenue for fiscal year 2025. This represents a 201.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Prenetics Global Limited (PRE) revenue grew by 201.7% year-over-year, from $30.6M to $92.4M in fiscal year 2025.
No, Prenetics Global Limited (PRE) reported a net loss of $37.7M in fiscal year 2025, with a net profit margin of -40.8%.
Prenetics Global Limited (PRE) had a gross margin of 52.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
Prenetics Global Limited (PRE) had an operating margin of -48.1% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
Prenetics Global Limited (PRE) had a net profit margin of -40.8% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
Prenetics Global Limited (PRE) has a return on equity of -24.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
Prenetics Global Limited (PRE) recorded an outflow of $22.0M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
Prenetics Global Limited (PRE) recorded an outflow of $21.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
Prenetics Global Limited (PRE) had $206.1M in total assets as of fiscal year 2025, including both current and long-term assets.
Prenetics Global Limited (PRE) invested $208K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
Prenetics Global Limited (PRE) invested $5.1M in research and development during fiscal year 2025.
Prenetics Global Limited (PRE) had a current ratio of 2.97 as of fiscal year 2025, which is generally considered healthy.
Prenetics Global Limited (PRE) had a liabilities-to-equity ratio of 0.32 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.
Prenetics Global Limited (PRE) had a return on assets of -18.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
Prenetics Global Limited (PRE) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $171.7M as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Prenetics Global Limited (PRE) trades at 1.9x sales, its market capitalization divided by $92.4M revenue, FY2025. The market capitalization is $171.7M as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Prenetics Global Limited (PRE) has a Piotroski F-Score of 5 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Prenetics Global Limited (PRE) reported a net loss of $37.7M while operations used $21.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Prenetics Global Limited (PRE) reported an operating loss of $44.5M against $258K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
Prenetics Global Limited (PRE) scores 46 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is the average of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. For Prenetics Global Limited it averages the 4 of 6 dimensions that can be computed; the others are left out rather than counted as zero. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.